The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
NCT03208998
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Chronic Hepatitis B Infection
Interventions
DRUG:
Peginterferon Alfa-2a
Sponsor
Beijing Ditan Hospital